Journal article · 2024
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.
Journal of Clinical Oncology, 42(16_suppl), 4110 · Published 1 June 2024 · DOI 10.1200/jco.2024.42.16_suppl.4110
In brief
“Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.” is a 2024 journal article by Arndt Vogel and 20 co-authors, published in Journal of Clinical Oncology. OpenAlex counts 39 citations as of 21 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 39
- Most cited in
- 2025 (26)
- Authors
- 21
Abstract
4110 Background: The phase 3 CARES-310 trial is the first to demonstrate significant progression-free survival (PFS) and overall survival (OS) benefits with immunotherapy plus an anti-angiogenic tyrosine kinase inhibitor (TKI) over standard TKI as first-line treatment for uHCC. In the primary analysis of PFS (data cut-off [DCO], May. 10, 2021) and interim analysis of OS… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Vogel, A., Chan, S. L., Ren, Z., Bai, Y., Gu, S., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Sultanbaev, A. V., Pazgan−Simon, M., Pisetska, M., Nip, T. K., Zhang, H., Du, J., Cheng, A., Kaseb, A. O., . . . CARES-310 Study Group. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. Journal of Clinical Oncology, 42(16_suppl), 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110
MLA 9
Vogel, Arndt, et al. “Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.” Journal of Clinical Oncology, vol. 42, no. 16_suppl, 2024, p. 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110.
Chicago
Vogel, Arndt, Stephen Lam Chan, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, Xiaoyan Lin, Zhendong Chen, et al. 2024. “Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.” Journal of Clinical Oncology 42 (16_suppl): 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110.
Harvard
Vogel, A. et al. (2024) ‘Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.’, Journal of Clinical Oncology, 42(16_suppl), p. 4110. doi:10.1200/jco.2024.42.16_suppl.4110.
IEEE
A. Vogel et al., “Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.,” Journal of Clinical Oncology, vol. 42, no. 16_suppl, p. 4110, 2024, doi: 10.1200/jco.2024.42.16_suppl.4110.
BibTeX
@article{vogel2024camrelizumab,
title = {{Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.}},
author = {Vogel, Arndt and Chan, Stephen Lam and Ren, Zhenggang and Bai, Yuxian and Gu, Shanzhi and Lin, Xiaoyan and Chen, Zhendong and Jia, Weidong and Jin, Yongdong and Guo, Yabing and Hu, Xiaohua and Sultanbaev, Alexander Valerievich and Pazgan−Simon, Monika and Pisetska, Margaryta and Nip, Tsz Keung and Zhang, Haisong and Du, Jinghua and Cheng, Ann‐Lii and Kaseb, Ahmed Omar and Qin, Shukui and CARES-310 Study Group},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {16_suppl},
pages = {4110},
doi = {10.1200/jco.2024.42.16_suppl.4110},
url = {https://doi.org/10.1200/jco.2024.42.16_suppl.4110}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 5 | |
| 2025 | 26 | |
| 2026 | 8 |
Topic and keywords
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- camrelizumab
- apatinib
- sorafenib
- unresectable hepatocellular carcinoma
- first-line therapy
- anti-PD-1 therapy
- VEGFR-2 inhibitors
- overall survival
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Vogel, A., Chan, S. L., Ren, Z., Bai, Y., Gu, S., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Sultanbaev, A. V., Pazgan−Simon, M., Pisetska, M., Nip, T. K., Zhang, H., Du, J., Cheng, A., Kaseb, A. O., . . . CARES-310 Study Group. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. Journal of Clinical Oncology, 42(16_suppl), 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110
How many times has this paper been cited?
39 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Arndt Vogel, Stephen Lam Chan, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Alexander Valerievich Sultanbaev and 9 more.
What is the DOI of this paper?
10.1200/jco.2024.42.16_suppl.4110, permanently at https://doi.org/10.1200/jco.2024.42.16_suppl.4110. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.